

RECEIVED

APR 08 2002

TECH CENTER 1600/2900

ATTORNEY DOCKET:
IMUNE-001A

Serial No. 09/730,174
Filed: AUGUST 20, 2001

1641
BOX 560

Certificate of Mailing under 37 CFR 1.8 or 37 CFR 1.10



I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON, D.C. 20231



I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10, Express Mail No. _____ addressed to:

on March 29, 2002
(Date)

Linda Pecchia

Signature

LINDA PECCHIA

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.


1. RESPONSE TO NOTICE TO COMPLY
2. COMPACT DISC OF SEQUENCE LISTINGS
3. COMPUTER PRINTOUT OF SEQUENCE LISTINGS
4. COPY OF "NOTICE TO COMPLY WITH REQUIREMENTS . . ."
- CONFIRMATION NO. 8045 Mailed 02/07/2002
5. TRANSMITTAL
6. RETURN POSTCARD

DISK TO STIC

DATE;



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.



TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Application Number	09/730,174
Filing Date	12/05/2000
First Named Inventor	Richard J. Zahradnik
Group Art Unit	1641
Examiner Name	Unknown
Attorney Docket Number	IMUNE-001A

Total Number of Pages in This Submission

10

ENCLOSURES (check all that apply)

- | | | |
|--|---|--|
| <input type="checkbox"/> Fee Transmittal Form
<input type="checkbox"/> Fee Attached
<input type="checkbox"/> Amendment / Reply
<input type="checkbox"/> After Final
<input type="checkbox"/> Affidavits/declaration(s)
<input type="checkbox"/> Extension of Time Request
<input type="checkbox"/> Express Abandonment Request
<input type="checkbox"/> Information Disclosure Statement
<input type="checkbox"/> Certified Copy of Priority Document(s)
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 | <input type="checkbox"/> Assignment Papers (for an Application)
<input type="checkbox"/> Drawing(s)
<input type="checkbox"/> Licensing-related Papers
<input type="checkbox"/> Petition
<input type="checkbox"/> Petition to Convert to a Provisional Application
<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address
<input type="checkbox"/> Terminal Disclaimer
<input type="checkbox"/> Request for Refund
<input type="checkbox"/> CD, Number of CD(s) _____ | <input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Status Letter
<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below):
*See Remarks |
|--|---|--|

Remarks

(1) compact disc of sequence listings
 (1) computer printout of sequence listings

Response to Notice to Comply

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm
or
Individual nameMatthew A. Newboles
STETINA BRUNDA GARRED & BRUCKER

Signature

Date

03/29/2002

CERTIFICATE OF MAILING

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231 on this date

3/29/2002

Typed or printed name

Linda Pecchia

Signature

Date

03/29/2002

Burden Hour Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231

RECEIVED
APR 08 2002
TECH CENTER 1600 2900

Case No.: IMUNE-001A



RECEIVED
APR 08 2002
TECH CENTER 1600-2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Richard J. Zahradnik

Group No.: 1641

Serial No.: 09/730,174

Examiner: Unknown

Filed: 12/05/2000

For: PTH 1-84 ANTIBODY
PREPARATION

RESPONSE TO NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT
APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID
SEQUENCE DISCLOSURES

ASSISTANT COMMISSIONER FOR PATENTS
WASHINGTON D C 20231

Dear Sir/Madam:

The following is responsive to the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures mailed February 7, 2002. In response thereto, Applicant has provided herewith both a compact disc providing an initial computer readable form (CRF) copy of the sequence listings, as well as a print out of such listings appearing in the application. Applicant respectfully submits that the substitute CRF copy complies with the requirements of 37 CFR 1.822 and 1.823, as verified in the verification summary report, a copy of which is also provided herewith.

Applicant further respectfully submits that the content of the sequence listing information provided in the accompanying compact disc and print out is identical to the written sequence listings appearing in the present application and does not include any new matter. Applicants previous amendment of November 14, 2001, is believed to have directed entry of the applicable sequence listings provided herewith into the present application.

Accordingly, Applicants respectfully submit that they have complied with the Notice to Comply mailed February 7, 2002, and request confirmation that the present application will proceed to examination. Early notice to that effect is respectfully requested. To the extent any outstanding issues continue to exist or if further information is required, please direct such inquires to Applicants' counsel listed below.

Respectfully submitted,

Date: 3/29/02

By: _____



Matthew A. Newboles

Registration No. 36,224

STETINA BRUNDA GARRED & BRUCKER

75 Enterprise, Suite 250

Aliso Viejo, CA 92656

(949) 855-1246



APR 8 4 2002

 OIPE JC17Z
 UNITED STATES PATENT AND TRADEMARK OFFICE
 TRADEMARK OFFICE

 COMMISSIONER FOR PATENTS
 UNITED STATES PATENT AND TRADEMARK OFFICE
 WASHINGTON, D.C. 20230
 www.uspto.gov

APPLICATION NUMBER	FILING/RECEIPT DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NUMBER
09/730,174	12/05/2000	Richard J. Zahradnik	IMUNE-001A

007663

 STETINA BRUNDA GARRED & BRUCKER
 75 ENTERPRISE, SUITE 250
 ALISO VIEJO, CA 92656

RECEIVED

 CONFIRMATION NO. 8045
 FORMALITIES LETTER

APR 8 2002



OC000000007439432

TECH CENTER 1600 2900

Date Mailed: 02/07/2002

NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant is given **TWO MONTHS FROM THE DATE OF THIS NOTICE** within which to file the items indicated below to avoid abandonment. Extensions of time may be obtained under the provisions of 37 CFR 1.136(a).

- A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing." Applicant must provide a substitute computer readable form (CRF) copy of the "Sequence Listing" and a statement that the content of the sequence listing information recorded in computer readable form is identical to the written (on paper or compact disc) sequence listing and, where applicable, includes no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b), or 1.825(d).

For questions regarding compliance to these requirements, please contact:

- For Rules Interpretation, call (703) 308-4216
- To Purchase PatentIn Software, call (703) 306-2600
- For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov

*A copy of this notice **MUST** be returned with the reply.*

 Customer Service Center
 Initial Patent Examination Division (703) 308-1202

PART 2 - COPY TO BE RETURNED WITH RESPONSE

PAGE:

1

VERIFICATION SUMMARY REPORT
PATENT APPLICATION

DATE: 03/26/2002

TIME: 14:03:49

INPUT SEQ: C:\WINDOWS\Desktop\SEQUENCE LISTING APPL. NO. 09-730-

134.TXT

GENERAL INFORMATION SECTION

3,<110> Zahradnik, R.J.
6,<120> Antibodies and Peptide Antigens for Producing Antibodies having a Selective
Binding Specificity to Bioactive Intact Parathyroid Hormone (PTH) 1-84
9,<130> IMMUNE-G01A
12,<140> 13-17, 19-21, 23-25
13,<150> 13-17, 19-21, 23-25
14,<160> 13-17, 19-21, 23-25

ERRORS SECTION

STATISTICS SUMMARY

Application Serial Number: US 09/730,134
Alpha or Numeric: Numeric
Application Class:
Application File Date: 1999-11-1
App. Title:
Software Application:
Total Number of Sequences: 17
Total Nucleotides: 0
Total Amino Acids: 154
Number of Errors: 0
Number of Warnings: 0
Number of Corrections: 0

PAGE:

1

ERROR LISTING
PATENT APPLICATION

DATE: 03/26/2002

TIME: 14:03:49

INPUT SEQ: C:\WINDOWS\Desktop\SEQUENCE LISTING APPL. NO. 09-730-

174.TXT